

Genkord Health and Biotechnology Services: Advancing Health Through Cellular Solutions

Founded in 2003, Genkord has been one of the pioneering initiatives in cord blood and stem cell banking in Turkey. Licensed by the Ministry of Health and TİTCK, the company has been successfully carrying out cellular processing, separation, and cryopreservation services for many years in its 400 m² GMP-certified cleanroom. With the completion of R&D projects supported by TÜBİTAK and KOSGEB, Genkord has continuously strengthened its scientific infrastructure. In 2015, it joined the Borsa Istanbul Private Market, and was awarded the **Horizon 2020 Seal of Excellence**, marking important steps in biotechnology entrepreneurship in our country.

Today, through its structure with PROMEDART Group, Genkord has become a center that not only provides classical stem cell banking but also serves a broad biotechnology ecosystem.

- **Stem Cell Studies:** Isolation, processing, and long-term storage of stem cells with high viability for clinical applications. By working on both cord blood and peripheral blood-derived stem cells, Genkord contributes to expanding Turkey's capacity in regenerative medicine.
- **Exosome Production:** Extracellular vesicles (exosomes) are innovative tools for transporting therapeutic RNAs and proteins. Genkord develops exosome platforms for research and therapeutic applications through GMP-compliant production and purification processes.
- **Quality and Regulation:** Cell production in compliance with GMP/ATMP standards, validation, traceability, and quality management systems, providing infrastructure ready for both national and international regulations.
- **R&D Capacity:** Continuous expansion of R&D pipelines focusing on cell derivatives (e.g., exosomes), novel bioengineering approaches, and laboratory innovations.

- **University Collaborations:** In 2025, Genkord signed a collaboration agreement with **CT3 – Center for Targeted Therapy Technologies** at Boğaziçi University, advancing its academic–industrial partnerships to a higher level.

Future Vision

In the coming years, Genkord aims to strengthen Turkey’s healthcare independence while actively positioning itself within the European biotechnology network. The company is also preparing for **Horizon Europe Projects** and has already established strong partnerships with leading academic and industrial stakeholders to build robust international consortia.

Strategic projects being developed and planned include:

Blood and Bone Marrow Separation Device: With a closed-system design and automated operation, this device provides a 10–30% improvement in product quality in the separation of blood components (erythrocytes, plasma, platelets, stem cells). Local production ensures simplified validation and cost advantages, making it a critical technology.

- **Neoantigen-Specific Lymphocyte (NSL) Project:** A novel approach in cancer immunotherapy, focusing on the production of T cells that target patient-specific tumor neoantigens. NSL is designed to offer superior efficacy in solid tumors with minimal side effects, providing advantages over classical CAR-T therapies.
- **Cancer Cell Banking:** Establishing a large-scale cancer cell repository to support research, preclinical validation, and the development of novel immunotherapies. This bank will serve as a strategic source for tumor biology studies and personalized treatment approaches.
- **Leukocyte Banking:**

A critical element for the future of immunotherapies, leukocyte banking ensures secure storage of both autologous (patient-derived) and allogeneic (donor-derived) cell sources for rapid access.

 - **Adult Leukocytes + HLA Silencing:** Enables the development of ready-to-use, “on-the-shelf” immune-invisible cell products.

